TAK, US8740602052

Takeda Pharmaceutical stock: Analysts raise average target to USD 20.74

Published on 10/22/2026 at 15:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda reported USD 7.50 billion quarterly revenue versus USD 7.13 billion expected. Takeda Pharmaceutical stock costs EUR 18.00 on October 22, 2026.

Analyst target and quarterly figures

TradingView reported an average target increase from USD 20.58 to USD 20.74 on October 15, 2026.
MarketBeat reported quarterly revenue of USD 7.50 billion against USD 7.13 billion expected.
Takeda Pharmaceutical stock costs EUR 18.00 at Lang & Schwarz on October 22, 2026 at 3:04 p.m. CEST.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) is being reassessed after the average analyst target rose from USD 20.58 to USD 20.74 on October 15, 2026, according to TradingView. Against the USD 19.93 NYSE price on October 21, 2026 at 4:00 p.m. ET, the USD 20.74 target stands 4.06 percent above the stock. At Lang & Schwarz, the euro quote was EUR 18.00 on October 22, 2026 at 3:04 p.m. CEST.

Revenue beat sets the baseline

Takeda's latest reported quarter delivered USD 7.50 billion in revenue against USD 7.13 billion expected, while earnings per share reached USD 0.95 versus a USD 0.41 estimate, MarketBeat reported on October 21, 2026. The revenue difference was USD 0.37 billion, or 5.19 percent above the estimate. These figures belong to the quarter reported on July 30, 2026, so the upcoming report will determine whether that performance continued.

Price remains near the yearly high

The NYSE range supplied for Takeda runs from USD 12.99 to USD 20.13. The USD 19.93 price was USD 0.20 below the high, equal to 0.99 percent, while the reported market capitalization was USD 62.4 billion. The valuation measure was a trailing P/E ratio of 56.59, and the finance quote listed a 3.00 percent dividend yield.

October 29 is the next date

Takeda announced on October 15, 2026 that it will present fiscal year 2026 second-quarter results on October 29, 2026. The company said the presentation and question-and-answer session will run from 7:00 p.m. to 8:15 p.m. JST, as stated in its Takeda release. The event is the next quantified checkpoint for revenue, earnings per share and management guidance.

Comparison with peers

Takeda: down 0.75 percent, P/E 56.59, market capitalization USD 62.4 billion.
Pfizer (NYSE, USD): down 0.83 percent, P/E 39.46, market capitalization USD 170.2 billion.
AbbVie (NYSE, USD): down 1.51 percent, P/E 80.22, market capitalization USD 503.1 billion.

What the target means for the stock

The target revision gives Takeda a measurable valuation marker before the October report, but its 4.06 percent distance from the latest NYSE price is narrower than the gap to the yearly high. The coming quarterly figures will provide the next direct test of the revenue comparison.

Takeda Pharmaceutical stock was trading at EUR 18.00 at Lang & Schwarz on October 22, 2026 at 3:04 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.